Maxim Group Starts BioHarvest Sciences (BHST) at Buy

Maxim Group analyst Anthony Vendetti initiates coverage on BioHarvest Sciences (NASDAQ: BHST) with a Buy rating and a price target of $12.00.

The analyst comments "Compelling valuation. We derive our 12-month price target of $12 by employing a 10-year DCF analysis with an 18% discount rate and a 3% perpetual growth rate. Shares currently trade at an EV/revenue multiple of 2.7x our 2025 estimate, below the peer average of 3.0x, excluding BHST. Our price target implies shares trading at an EV/revenue multiple of 5.2x our 2025 revenue estimate, a premium to peers, which we believe is justified due to the company’s cutting-edge technology, wellabove average revenue growth, and sizable market opportunities."

For an analyst ratings summary and ratings history on BioHarvest Sciences click here. For more ratings news on BioHarvest Sciences click here.

Shares of BioHarvest Sciences closed at $6.19 yesterday.

You May Also Be Interested In

• Jefferies Resumes Agilent (A) at Hold
• Us Military Completes Another Round Of Strikes Against Iran - Bloomberg
• Freedom Capital Starts Tempus AI Inc (TEM) at Hold